Immuron Travelan® Global sales up 216%
27 avr. 2022 06h00 HE
|
Immuron Limited
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. ...
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
19 avr. 2022 07h33 HE
|
Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
13 janv. 2022 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
12 janv. 2022 06h00 HE
|
Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
15 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
US DoD Naval Medical Research Center Clinical Update
10 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
20 juil. 2020 06h00 HE
|
Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
19 juin 2020 06h00 HE
|
Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
09 juin 2020 06h00 HE
|
Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
21 nov. 2019 07h00 HE
|
Immuron Limited
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to prevent TD planned for...